title: [Fracture risk associated with drugs other than glucocorticoids].
abstract: Many drugs influence fracture risk besides glucocorticoid, a most common cause of drug-induced osteoporosis. It is well established that drugs used for anti-sex steroids therapy for breast and prostate cancers increase fracture risk, including GnRH agonists, aromatase inhibitors, and anti-androgens. Increased fracture risk is also established with anti-diabetic thiazolidinediones by a randomized control study as well as meta analysis of observational studies. Multiple observational studies have indicated increased fracture risks with selective serotonin reuptake inhibitors and proton pump inhibitors. Excess thyroid hormones, anti epileptics, heparin, warfarin, may also be associated with an increase in fracture risks. On the contrary, statins, thiazides, beta blockers, and nitrates may be associated with decreased fracture risks.
authors.affiliation: Third Department of Medicine, Teikyo University Chiba Medical Center, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Okazaki
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000009:adverse effects*; D000927:Anticonvulsants / Q000009:adverse effects; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D005598:Fractures, Spontaneous / Q000139:chemically induced* / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D009566:Nitrates / Q000494:pharmacology / Q000627:therapeutic use; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control; D054328:Proton Pump Inhibitors / Q000009:adverse effects*; D012306:Risk; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000009:adverse effects*; D013963:Thyroid Hormones / Q000009:adverse effects; D014859:Warfarin / Q000009:adverse effects
chemical_list: D000319:Adrenergic beta-Antagonists; D000726:Androgen Antagonists; D000927:Anticonvulsants; D047072:Aromatase Inhibitors; D005938:Glucocorticoids; D007987:Gonadotropin-Releasing Hormone; D006493:Heparin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D009566:Nitrates; D054328:Proton Pump Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors; D049993:Sodium Chloride Symporter Inhibitors; D045162:Thiazolidinediones; D013963:Thyroid Hormones; D014859:Warfarin; C089946:2,4-thiazolidinedione